CRPC
Metastatic castration-resistant prostate cancer
Advertisement
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Enzalutamide was associated with improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate.
The study presented the results of cohorts 4 and 5 from the phase 2 KEYNOTE-199 study.
The impact of potential comorbidities and concomitant medication interactions in ARPIs are not well understood.
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
The study’s primary end points were the incidence of all-grade or grade 3 and higher cardiovascular events.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Enhancing Genetic Testing Rates in Metastatic Prostate Cancer: Trends, Challenges, and Opportunities
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC. 
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
The PSMAfore trial shows [177Lu]Lu-PSMA-617 significantly improves rPFS, ORR, and PSA50 in taxane-naive patients with mCRPC.
Dr. Denmeade highlights his research on blood-based markers of differential efficacy of BAT and enzalutamide in TRANSFORMER.
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.